MX2022012178A - Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. - Google Patents
Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.Info
- Publication number
- MX2022012178A MX2022012178A MX2022012178A MX2022012178A MX2022012178A MX 2022012178 A MX2022012178 A MX 2022012178A MX 2022012178 A MX2022012178 A MX 2022012178A MX 2022012178 A MX2022012178 A MX 2022012178A MX 2022012178 A MX2022012178 A MX 2022012178A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- disclosed
- preparing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 101150092630 Myt1 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en el presente documento pueden ser inhibidores de la cinasa inhibidora de cdc2 específica de treonina y tirosina (Myt1). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003745P | 2020-04-01 | 2020-04-01 | |
| PCT/CA2021/050443 WO2021195781A1 (en) | 2020-04-01 | 2021-04-01 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012178A true MX2022012178A (es) | 2022-12-08 |
Family
ID=77927736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012178A MX2022012178A (es) | 2020-04-01 | 2021-04-01 | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230151014A1 (es) |
| EP (1) | EP4126879A4 (es) |
| JP (1) | JP2023521633A (es) |
| KR (1) | KR20230011279A (es) |
| CN (1) | CN115916783A (es) |
| AU (1) | AU2021250744A1 (es) |
| BR (1) | BR112022019611A2 (es) |
| CA (1) | CA3177200A1 (es) |
| CO (1) | CO2022015638A2 (es) |
| CR (1) | CR20220558A (es) |
| EC (1) | ECSP22083904A (es) |
| IL (1) | IL296934A (es) |
| MX (1) | MX2022012178A (es) |
| WO (1) | WO2021195781A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115811976A (zh) * | 2020-04-01 | 2023-03-17 | 修复治疗公司 | 使用myt1抑制剂的方法 |
| EP4221702A1 (en) * | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| WO2022213204A1 (en) * | 2021-04-07 | 2022-10-13 | Repare Therapeutics Inc. | Combination therapies including myt1 inhibitors |
| WO2023155870A1 (en) * | 2022-02-18 | 2023-08-24 | Insilico Medicine Ip Limited | Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof |
| WO2023155892A1 (en) * | 2022-02-18 | 2023-08-24 | Insilico Medicine Ip Limited | Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof |
| WO2023174329A1 (en) * | 2022-03-15 | 2023-09-21 | Insilico Medicine Ip Limited | Heteroaromatic compounds as pkmyt1 inhibitors and use thereof |
| WO2023198199A1 (zh) * | 2022-04-15 | 2023-10-19 | 先声再明医药有限公司 | 膜缔合酪氨酸和苏氨酸激酶抑制剂 |
| WO2023220831A1 (en) * | 2022-05-18 | 2023-11-23 | Repare Therapeutics Inc. | Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same |
| WO2023249563A1 (en) * | 2022-06-23 | 2023-12-28 | Engine Biosciences Pte. Ltd. | Compounds and method for pkmyt1 inhibition |
| WO2024012409A1 (zh) * | 2022-07-12 | 2024-01-18 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| WO2024041440A1 (en) * | 2022-08-24 | 2024-02-29 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| WO2024048687A1 (ja) * | 2022-08-31 | 2024-03-07 | 中外製薬株式会社 | Ｍｙｔ１阻害剤と化学療法剤を併用する、ｒｂ１の機能低下が生じている患者のがんの治療剤及び治療方法 |
| WO2024061343A1 (zh) * | 2022-09-23 | 2024-03-28 | 先声再明医药有限公司 | 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002531504A (ja) * | 1998-12-07 | 2002-09-24 | スミスクライン・ビーチャム・コーポレイション | Ｍｙｔ１キナーゼ阻害剤 |
| CO5261594A1 (es) * | 2000-03-02 | 2003-03-31 | Smithkline Beecham Corp | Inhibidores de myt1 cinasa |
| WO2015073528A1 (en) * | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US9856259B2 (en) * | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
-
2021
- 2021-04-01 US US17/916,760 patent/US20230151014A1/en active Pending
- 2021-04-01 IL IL296934A patent/IL296934A/en unknown
- 2021-04-01 BR BR112022019611A patent/BR112022019611A2/pt unknown
- 2021-04-01 CA CA3177200A patent/CA3177200A1/en active Pending
- 2021-04-01 EP EP21780725.4A patent/EP4126879A4/en active Pending
- 2021-04-01 CN CN202180039259.5A patent/CN115916783A/zh active Pending
- 2021-04-01 CR CR20220558A patent/CR20220558A/es unknown
- 2021-04-01 KR KR1020227038112A patent/KR20230011279A/ko unknown
- 2021-04-01 AU AU2021250744A patent/AU2021250744A1/en active Pending
- 2021-04-01 MX MX2022012178A patent/MX2022012178A/es unknown
- 2021-04-01 WO PCT/CA2021/050443 patent/WO2021195781A1/en unknown
- 2021-04-01 JP JP2022559965A patent/JP2023521633A/ja active Pending
-
2022
- 2022-10-27 EC ECSENADI202283904A patent/ECSP22083904A/es unknown
- 2022-10-31 CO CONC2022/0015638A patent/CO2022015638A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115916783A (zh) | 2023-04-04 |
| CO2022015638A2 (es) | 2022-11-18 |
| EP4126879A1 (en) | 2023-02-08 |
| WO2021195781A1 (en) | 2021-10-07 |
| US20230151014A1 (en) | 2023-05-18 |
| KR20230011279A (ko) | 2023-01-20 |
| CR20220558A (es) | 2022-12-12 |
| CA3177200A1 (en) | 2021-10-07 |
| BR112022019611A2 (pt) | 2022-11-29 |
| JP2023521633A (ja) | 2023-05-25 |
| AU2021250744A1 (en) | 2022-11-17 |
| IL296934A (en) | 2022-12-01 |
| ECSP22083904A (es) | 2022-11-30 |
| EP4126879A4 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012178A (es) | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. | |
| PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| EA202092320A1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2022006865A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. | |
| MX2021003517A (es) | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. | |
| WO2021195782A8 (en) | Methods of using myt1 inhibitors | |
| ME00142B (me) | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze | |
| GEP20094845B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| CL2011000124A1 (es) | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| ZA200802075B (en) | MEK inhibitors and methods of their use | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| MX2021014455A (es) | Inhibidores de proteina cinasas dependientes de adn. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| MX2021013602A (es) | Inhibidores de jak. |